GLP-1 Revolution and Hidden Micronutrient Deficiency
No Cover

GLP-1 Revolution and Hidden Micronutrient Deficiency

Handbook for Physicians, Diabetologists, Cardiologists and Metabolic Specialists

Dr A M Thirugnanam

GLP-1 receptor agonists have rewritten cardiometabolic medicine. The weight loss they produce brings a hidden cost that few clinicians are screening for.

Semaglutide and tirzepatide now cut MACE, heart-failure events and kidney decline in patients with and without diabetes. Yet rapid weight loss, reduced food intake and slower gastric emptying quietly deplete magnesium, vitamin D, vitamin B12, iron, zinc, CoQ10 and protein, and those deficits matter to the heart.

GLP-1 Revolution and Hidden Micronutrient Deficiency is an 18-chapter international handbook by Dr A M Thirugnanam, a senior interventional cardiologist and medical educator. It brings the full cardiovascular evidence base together with a practical, protocol-driven approach to protecting patients from nutritional harm.

The evidence, trial by trial
• LEADER, SUSTAIN-6, PIONEER 6, REWIND, EXSCEL, HARMONY and SOUL
• SELECT, a cardiovascular benefit in people without diabetes
• FLOW: semaglutide in diabetic kidney disease
• STEP-HFpEF and SUMMIT: incretins in obesity-related HFpEF
• SURPASS-2, the SURMOUNT programme and SURPASS-CVOT: tirzepatide head-to-head

Mechanisms and organ systems
• Myocardial protection, epicardial adipose tissue, fibrosis and the NLRP3 inflammasome
• Atherosclerosis, plaque stabilisation and endothelial function
• Heart failure, blood pressure, arterial stiffness, lipids, the cardiorenal axis and atrial fibrillation

The micronutrient dimension
• Magnesium, CoQ10, vitamin D, omega-3 fatty acids, B vitamins, selenium and zinc in cardiovascular health
• How GLP-1-driven weight loss causes depletion
• A three-tier, evidence-based supplementation and monitoring protocol

Prescribing in the real world
• Combination therapy with SGLT2 inhibitors, finerenone, PCSK9 inhibitors, ARNI, icosapent ethyl and antithrombotics
• Special populations: the elderly and frail, women, the South Asian “thin-fat” phenotype, advanced CKD, liver disease, transplant recipients, adolescents and perioperative care
• Safety: GI tolerability, pancreatitis, thyroid, gallbladder, retinopathy and drug interactions, with a pre-prescribing checklist
• ADA, ACC, ESC and AACE guidance, cost-effectiveness and access barriers
• Next-generation agents: retatrutide, CagriSema, survodutide and oral orforglipron

Practical tools: chapter roadmaps, clinical-pearl boxes, evidence tables, dosing and titration charts, an interaction matrix, a glossary and a curated bibliography.

Ideal for cardiologists, diabetologists, endocrinologists, physicians, obesity and metabolic specialists, and fellows who prescribe or co-manage GLP-1 therapy.

Book Info

Publisher Academy of Elite Doctors
Release Date 2026-05-05
Page Count 493 Pages
File Size 1.9 MB
Language en-US

No download link available yet. You can .

Related Books

Similar recommendations you might enjoy

Join Telegram